The effects of acute and sub-chronic MDMA were assessed using a procedure designed to test rodent working memory capacity: the odor span task (OST). Rats were trained to select an odor that they had not previously encountered within the current session, and the number of odors to remember was incremented up to 24 during the course of each session. In order to separate drug effects on the OST from more general performance impairment, a simple olfactory discrimination was also assessed in each session. In Experiment 1, acute doses of MDMA were administered prior to select sessions. MDMA impaired memory span in a dose-dependent fashion, but impairment was seen only at doses (1.8 and 3.0 mg/kg) that also increased response omissions on both the simple discrimination and the OST. In Experiment 2, a subchronic regimen of MDMA (10.0 mg/kg, twice daily over four days) was administered after OST training. There was no evidence of reduced memory span following sub-chronic MDMA, but a temporary increase in omission errors on the OST was observed. In addition, rats exposed to sub-chronic MDMA showed delayed learning when the simple discrimination was reversed. Overall, the disruptive effects of both acute and sub-chronic MDMA appeared to be due to non-mnemonic processes, rather than effects on specific memory functions.
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Introduction
Research with recreational ecstasy users has revealed deficits on a number of cognitive tasks. A history of heavy ecstasy use is associated with impaired performance on tests of attention, learning and working memory with simple cognitive tasks (e.g., reaction time) often unaffected, and more complex tasks involving higher processing loads more severely affected (Montgomery & Fisk, 2008; Murphy, Wareing, Fisk, & Montgomery, 2009; Nulsen, Fox, & Hammond, 2010; Parrott, 2013) . Of course, these studies have many limitations including the accuracy of the self-reported drug histories on which they are based and the complication that most ecstasy users are also multiple drug users. Further, pills believed by users to be ecstasy may or may not contain only MDMA (Sherlock, Wolff, Hay, & Conner, 1999) . Thus, it is difficult to determine whether the differences between controls and ecstasy users are actually based on MDMA use. Indeed, when groups of ecstasy users are compared with groups of participants who do not use ecstasy, but are matched with respect to use of marijuana or other drugs, several studies have found comparable cognitive deficits (e.g., Croft, Mackay, Mills, & Gruzelier, 2001; Dafters, Hoski, & Talbot, 2004; de Sola et al., 2008) , although others have found more severe deficits in ecstasy users (Daumann et al., 2005; Nulsen et al., 2010) . Due to these difficulties in interpretation and given the ethical restrictions associated with administering MDMA to humans, preclinical studies using non-human subjects, particularly rodents, have an important role in the investigation of these cognitive disruptions.
Numerous studies have shown that acute MDMA administration can impair performance on learning and working memory tasks in rodents (e.g., Arias-Cavieres et al., 2010; Braida, Pozzi, Cavallini, & Sala, 2002; Byrne, Baker, & Poling, 2000; Galizio, McKinney, Cerutti, & Pitts, 2009; Galizio, Byrd, Robinson, Hawkey, & Rayburn-Reeves, 2014; Harper, Wisnewski, Hunt, & Schenk, 2005; Marston, Reid, Lawrence, Olverman, & Butcher, 1999) . However, whether these disruptions are specific to working memory processes is not clear. For example, Harper et al. (2005) showed that MDMA effects on delayed matching-to-sample were independent of delay, that is, comparable levels of disruption were observed under conditions of no delay (which presumably do not involve working memory), as well as with delays. Similarly, Galizio et al. (2014) found that MDMA increased latency to locate the hidden platform in the Morris Swim Task, but only at doses that also impaired overall perceptual-motor ability. Finally, Kay, Harper, and Hunt (2010) found that acute doses of MDMA impaired performance on a reference memory version of the radial
